Compare BBAR & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBAR | IMNM |
|---|---|---|
| Founded | 1886 | 2006 |
| Country | Argentina | United States |
| Employees | N/A | 177 |
| Industry | Commercial Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 1997 | 2020 |
| Metric | BBAR | IMNM |
|---|---|---|
| Price | $13.60 | $22.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $17.00 | ★ $32.80 |
| AVG Volume (30 Days) | 481.8K | ★ 881.4K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | $18.32 | N/A |
| Revenue Next Year | $11.04 | $1,127.34 |
| P/E Ratio | $26.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.76 | $7.15 |
| 52 Week High | $23.10 | $27.65 |
| Indicator | BBAR | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 35.38 | 50.89 |
| Support Level | $13.13 | $19.23 |
| Resistance Level | $17.10 | $22.86 |
| Average True Range (ATR) | 0.74 | 0.96 |
| MACD | -0.27 | -0.10 |
| Stochastic Oscillator | 5.22 | 23.54 |
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.